ADVERTISEMENT
Dr Baik Discusses Patritumab Deruxtecan for EGFR+ NSCLC
06/16/2021
Christina Baik, MD, MPH, Seattle Cancer Care Alliance, Thoracic/Head and Neck, Department of Medicine, Division of Medical Oncology, Washington, discusses the efficacy and safety of patritumab deruxtecan (HER3-DXd), in EGFR inhibitor-resistant, EGFR-mutated non-small cell lung cancer (NSCLC).
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Visit the OLN Excellence Forums
Advertisement
Advertisement
Advertisement